[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2692345T3 - Kompozycja farmaceutyczna do zapobiegania lub leczenia zwyrodnienia plamki żółtej - Google Patents

Kompozycja farmaceutyczna do zapobiegania lub leczenia zwyrodnienia plamki żółtej

Info

Publication number
PL2692345T3
PL2692345T3 PL12764888T PL12764888T PL2692345T3 PL 2692345 T3 PL2692345 T3 PL 2692345T3 PL 12764888 T PL12764888 T PL 12764888T PL 12764888 T PL12764888 T PL 12764888T PL 2692345 T3 PL2692345 T3 PL 2692345T3
Authority
PL
Poland
Prior art keywords
preventing
pharmaceutical composition
macular degeneration
treating macular
treating
Prior art date
Application number
PL12764888T
Other languages
English (en)
Inventor
Kyu-Yang Yi
Sung-Eun Yoo
Nack-Jeong Kim
Jee-Hee Suh
Choun-Ki Joo
Jun-Sub Choi
Jae-Sik Yang
Geun-Hyeog Lee
Yun-Seok Cho
Jin-Ha Park
Hye-Sung Lee
Original Assignee
Korea Research Institute Of Chemical Technology
Catholic University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute Of Chemical Technology, Catholic University Industry Academic Cooperation Foundation filed Critical Korea Research Institute Of Chemical Technology
Publication of PL2692345T3 publication Critical patent/PL2692345T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL12764888T 2011-03-30 2012-03-29 Kompozycja farmaceutyczna do zapobiegania lub leczenia zwyrodnienia plamki żółtej PL2692345T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110028946 2011-03-30
PCT/KR2012/002310 WO2012134187A2 (ko) 2011-03-30 2012-03-29 황반변성 예방 또는 치료용 약학 조성물
EP12764888.9A EP2692345B1 (en) 2011-03-30 2012-03-29 Pharmaceutical composition for preventing or treating macular degeneration

Publications (1)

Publication Number Publication Date
PL2692345T3 true PL2692345T3 (pl) 2018-03-30

Family

ID=46932137

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12764888T PL2692345T3 (pl) 2011-03-30 2012-03-29 Kompozycja farmaceutyczna do zapobiegania lub leczenia zwyrodnienia plamki żółtej

Country Status (15)

Country Link
US (2) US20140018402A1 (pl)
EP (1) EP2692345B1 (pl)
JP (1) JP6099209B2 (pl)
KR (1) KR101891078B1 (pl)
CN (2) CN103501782A (pl)
AU (1) AU2012237066B2 (pl)
BR (1) BR112013022124A2 (pl)
CA (1) CA2831025C (pl)
DK (1) DK2692345T3 (pl)
ES (1) ES2643377T3 (pl)
HU (1) HUE036473T2 (pl)
PL (1) PL2692345T3 (pl)
PT (1) PT2692345T (pl)
RU (1) RU2576380C2 (pl)
WO (1) WO2012134187A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
KR102484846B1 (ko) * 2015-11-27 2023-01-05 한림제약(주) 벤조피란 유도체의 정제방법, 이의 결정형 및 상기 결정형의 제조방법
KR102478553B1 (ko) * 2018-02-28 2022-12-16 한림제약(주) 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제
KR102282535B1 (ko) * 2019-11-21 2021-07-27 한국화학연구원 방사선 조사에 의한 조직 또는 세포 손상의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
NZ518420A (en) * 1999-11-05 2004-02-27 Sod Conseils Rech Applic Heterocyclic compounds having an inhibitory activity on calpains or a trapping activity on reactive oxygen species (ROS's) and their use as medicines
WO2003084464A2 (en) * 2002-04-10 2003-10-16 Dongbu Hannong Chemical Co., Ltd Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
KR100492252B1 (ko) * 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
WO2006000607A1 (es) * 2004-06-23 2006-01-05 Neurotec Pharma, S.L. Uso de activadores de los canales de katp (kco), en particular el diazóxido, en el tratamiento de la inflamación crónica de snc asociada a algunas efermedades
MX2008006379A (es) * 2005-11-29 2009-03-03 Smithkline Beecham Corp Metodo de tratamiento.
AU2006331790A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
AU2008218783A1 (en) * 2007-02-22 2008-08-28 Colby Pharmaceutical Company Hydroxylamine compounds and methods of their use
ATE519756T1 (de) * 2007-05-25 2011-08-15 Santen Pharmaceutical Co Ltd Prophylaktikum bzw. therapeutikum für altersbedingte makuladegeneration
WO2009116076A2 (en) * 2008-02-19 2009-09-24 M. J. Biopharm Pvt.Ltd. Sterile opthalmic preparations and a process for preparation thereof
TW201105363A (en) * 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration

Also Published As

Publication number Publication date
KR101891078B1 (ko) 2018-08-23
CA2831025A1 (en) 2012-10-04
WO2012134187A3 (ko) 2012-12-06
JP2014509643A (ja) 2014-04-21
US10485786B2 (en) 2019-11-26
PT2692345T (pt) 2017-10-19
CN103501782A (zh) 2014-01-08
HUE036473T2 (hu) 2018-07-30
RU2013147449A (ru) 2015-05-10
US20180221343A1 (en) 2018-08-09
AU2012237066A1 (en) 2013-09-26
WO2012134187A2 (ko) 2012-10-04
KR20120112162A (ko) 2012-10-11
RU2576380C2 (ru) 2016-03-10
ES2643377T3 (es) 2017-11-22
EP2692345A2 (en) 2014-02-05
JP6099209B2 (ja) 2017-03-22
AU2012237066B2 (en) 2016-08-25
CN105380946A (zh) 2016-03-09
US20140018402A1 (en) 2014-01-16
DK2692345T3 (en) 2017-10-30
EP2692345A4 (en) 2014-08-27
EP2692345B1 (en) 2017-07-19
CA2831025C (en) 2018-09-04
BR112013022124A2 (pt) 2019-09-10

Similar Documents

Publication Publication Date Title
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
AP3864A (en) Pharmaceutical composition
HUE054621T2 (hu) Gyógyászáti készítmény, kezelési eljárások és alkalmazásaik
GB201118232D0 (en) Pharmaceutical composition
HK1202248A1 (en) Compositions and methods for treating neurodegenerative disease
EP2558103A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM
EP2709614A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER
HK1202246A1 (en) Compositions and methods for treating neurodegenerative disease
HK1189158A1 (en) Pharmaceutical composition
EP2668186A4 (en) PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES
IL236112B (en) Pharmaceutical preparations containing verbena for the treatment or prevention of neurodegenerative diseases
EP2774917A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
HK1187336A1 (en) Pharmaceutical composition comprising pyridone derivatives
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
HUE036473T2 (hu) Gyógyászati kompozíció makuladegeneráció megelõzésére vagy kezelésére
EP2727593A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL
EP2926817A4 (en) STABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS
EP2711010A4 (en) PHARMACEUTICAL COMPOSITION
HUP1100444A2 (en) Pharmaceutical composition
EP2826488A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS
PL2663318T3 (pl) Kompozycja farmaceutyczna do leczenia raka
SI2497774T1 (sl) Derivati dihidrooksazolobenzodiazepinona, postopki za njihovo pripravo in farmacevtski sestavki, ki te spojine vsebujejo
EP2730288A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FIBROSIS
EP2785343A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA
EP2712621A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE DISEASES